Results 71 to 80 of about 28,637 (186)
Mediterranean Journal of Hematology and Infectious Diseases, 2009 Heart disease is the leading cause of mortality and one of the main causes of morbidity in beta-thalassemia. Patients with homozygous thalassemia may have either a severe phenotype which is usually transfusion dependent or a milder form that is ...
Athanasios Aessopos, Vasilios Berdoukas
doaj +1 more source
Diving deep into chelation therapy for coronary artery disease: a review [PDF]
, 2019 Chelation therapy is still a mainstay therapy when it comes to dealing with heavy metal intoxication. The ability of various chelators to bind metal and other chemical molecules led to the idea whether chelation therapy can be used as an alternative ...
Santosa Putra, Iwan Cahyo +1 more
core +2 more sources
Mediterranean Journal of Hematology and Infectious Diseases, 2018 Sickle cell disease patients often need regular blood transfusions to improve both the quality of life and survival from the veno-occlusive complications of the disease.
SOPHIA DELICOU
doaj +1 more source
Understanding coronary artery disease patients’ decisions regarding the use of chelation therapy for coronary artery disease: Descriptive decision modeling [PDF]
, 2012 BackgroundA considerable number of patients receive chelation therapy to treat their coronary artery disease. However, there is no current empirical evidence to support its use.AimTo better understand patient's decision-making processes regarding the use
W.A. Ghali +11 more
core +1 more source
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes [PDF]
, 2016 Christina N Kontoghiorghe, George J Kontoghiorghes Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus Abstract: The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East, and
Kontoghiorghes GJ, Kontoghiorghe CN
core
Sex and Gender Differences in Iron Chelation
BiomedicinesBackground/Objectives: In the absence of physiological mechanisms to excrete excessive iron, the administration of iron chelation therapy is necessary.
Sarah Allegra +3 more
doaj +1 more source
Failure of chelation therapy in lead nephropathy. [PDF]
, 1984 A patient with lead nephropathy and gout was treated with three months of edetic acid chelation. The therapy resulted in normalization of a previously abnormal result of edetic acid lead mobilization test.
Braden, G L +2 more
core
The Western journal of medicine, 1975 This statement was prepared in response to a request made to the Clinical Pharmacology Service at the University of California, San Francisco to evaluate the potential therapeutic uses and the possible toxicities of chelation therapy. The question arose in regard to the use of ethylene tetraacetic acid (EDTA) in the treatment of atherosclerotic ...
P C, Carven, H F, Morrelli
openaire +1 more source
Beliefs of Jordanian Children with Thalassemia toward Using Iron Chelation Therapy [PDF]
, 2016 Adherence to thalassemia treatment including chelation drugs is influenced by numerous factors. This study aims to explore beliefs about iron chelation therapy and adherence to this medication in Jordanian children with thalassemia major.
Ghada Mohammad, Abu Shosha
core
Copper Chelation as an Antiangiogenic Therapy
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2004 Angiogenesis is now recognized as a crucial process in tumor development. Copper appears to act as an essential cofactor for several angiogenic growth factors, and both copper metabolism and ceruloplasmin expression are upregulated in many tumors. The role of copper chelators has been investigated in animal models with promising results.
S A, Lowndes, A L, Harris
openaire +2 more sources